{"id":43865,"key":"Global_Health_Medical_Device_Compendium/Uniject","title":"Global Health Medical Device Compendium/Uniject","latest":{"id":1267791,"timestamp":"2026-09-10T14:30:02Z"},"content_model":"wikitext","license":{"url":"https://www.appropedia.org/Appropedia:Copyrights","title":"CC-BY-SA-4.0"},"source":"[[File:Uniject.jpg|thumb]]\n\n{{GHMDC device data\n| health-topic = Maternal mortality\n| classification = Treatment\n| scope = Commercialized\n| type = Disposable needle\n| manufacturer-location = New Jersey, United States\n}}\n\nIn the developing world, needles in a medical setting are often reused due to the scarcity of resources. However, reusing old (and possibly contaminated) needles increases the risk of HIV transmission. There was a need for a single-use, safe syringe in order to ensure safe injections.\n\n== Detailed description of the solution ==\n\nThe Uniject is a single-use needle, designed with a pre-filled drug delivery container that cannot be refilled. This type of needle is effective in preventing \"needle sharing\" because it can only be used once and provides a sterile injection each time. It is also user-friendly in that medical personnel can be trained to use the Uniject in under two hours (PATH, n.d.). It is compact, convenient, easy to store and increases dosage precision.\n\n== Designed by ==\n\n* Designed by: This device was designed by PATH.\n* Manufacturer (if different): It is licensed and manufactured by Becton, Dickinson and Company (BD).\n\n== When and where it was tested/implemented ==\n\nThis device was tested in Argentina (Althabe, 2011), Angola (Strand, 2005), Indonesia (\"Cost\", 2003) and Vietnam (\"Oxytocin\", 2003).\n\n== Funding Source ==\n\nThis device has received funding from USAID, BD and UNICEF.\n\n== References ==\n\n=== Peer-reviewed publication ===\n\nAlthabe, F., Mazzoni, A., Cafferata, M. L., Gibbons, L., Karolinski, A., Armbruster, D., et al.(2011). Using Uniject to increase the use of prophylactic oxytocin for management of the third stage of labor in Latin America. International Journal of Gynecology and Obstetrics, 114, 184-189.\n\nStrand, R. T., Silva, F. D., Jangsten, E., & Bergstrom, S. (2005). Postpartum hemorrhage: a prospective, comparative study in Angola using a new disposable device for oxytocin administration. Acta Obstetricia et Gynecologica Scandinavica, 84, 260-265.\n\nTsu, V. D., Levin, C., Tran, M. P., Huang, M. V., & Luu, H. T. (2009). Cost-effectiveness analysis \tof active management of third-stage labour in Vietnam. Health Policy and Planning, 24, 438-444.\n\nTsu, V., Sutanto, A., Vaidya, K., Coffey, P., & Widjaya, A. (2003). Oxytocin in prefilled Uniject injection devices for managing third-stage labor in Indonesia. International Journal of Gynecology and Obstetrics, 83, 103-111.\n\n=== Other internally generated reports ===\n\nPATH: Uniject. (n.d.). PATH: A catalyst for global health. Retrieved October 21, 2012. Link available [https://web.archive.org/web/20140209230859/http://path.org/our-work/uniject.php here].\n\nUniJect. (n.d.). BD. Retrieved October 21, 2012. PDF available [http://www.bd.com/responsibility/feature/pdf/uniject.pdf here].\n\n{{Page data\n| sdg = SDG03 Good health and well-being\n| license = CC-BY-SA-3.0\n| language = en\n}}"}